Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)

GlaxoSmithKline19 enrolled

Overview

WAS is a rare primary immune deficiency disease caused by genetic mutation and is more common in males than females. The purpose of this study is to understand experiences of WAS subjects and caregivers to identify important concepts of interest that could be measured in future Phase IIIb trials. This is a qualitative cross-sectional study that will include a sample of approximately, 8 subjects with WAS and 13 caregivers of subjects with a diagnosis of WAS in the United States, United Kingdom and France. A 60 to 90 minute open-ended interview will be conducted over the telephone or video conference that will be audio-recorded for subsequent transcription. The aim of these interviews is to obtain subject and caregiver perspectives on the impact of WAS and its associated treatments on quality of life and experiences of living with WAS.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Wiskott-Aldrich Syndrome

Interventions

Patient Interview guideOTHER

The interviewer will conduct the interview for subjects with WAS using a semi-structured patient interview guide.

Eligibility

Sex: MALEMin age: 12 YearsMax age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: Subjects: * Male adolescents or young adults ranging in age from 12 through 30 years old. * Diagnosis of WAS defined by WAS genetic mutation with a clinical score \>=1 or self-reported disease severity. * Subjects who are "conservatively managed" or have not received treatment for WAS; a maximum of 5 subjects who have received a hematopoietic stem cell transplant within the preceding two years. * Able to read, speak, and understand English or French sufficiently to complete all assessments. * Willing and able to participate in an audio-recorded, telephone or video conference session, including adherence to the interview instructions and completion of all questionnaires. * Parent/guardian/patient signed informed consent. Caregivers: * Caregivers of children \>=2 years of age diagnosed with WAS; at least 5 caregivers of subjects under the age of 8. * Caregivers of subjects with a diagnosis of WAS defined by WAS genetic mutation with a clinical score \>=1 or self-reported disease severity. * Caregivers of subjects who are "conservatively managed" or have not received treatment for WAS; At least 2 caregivers of subjects who have received a hematopoietic stem cell transplant within the preceding two years. * Caregivers are defined as primary caregiver. * Able to read, speak, and understand English or French sufficiently to complete all assessments. * Willing and able to participate in an audio-recorded, telephone or video conferencing interview session, including adherence to the interview instructions and completion of all questionnaires. * Caregivers of Wiskott-Aldrich patients can be of any age or gender and do not have to follow the patient inclusion criteria, as long as their child/patient meets the inclusion criteria, as outlined. Exclusion Criteria: Subjects * Subjects who have previously received gene therapy treatment Caregivers * Caregivers of subjects who have previously received gene therapy treatment * Professional caregivers (that is, at home nurse or equivalent).

Outcomes

Primary Outcomes

Number of subject reported perspectives on WAS

Open-ended interviews will be conducted in adolescent and adult subjects to understand their perspective on WAS.

Time frame: Up to 90 minutes

Number of caregiver reported perspectives on WAS

Open-ended interviews will be conducted in caregivers of subjects with WAS to understand their perspective on WAS.

Time frame: Up to 90 minutes

Number of subject reported preventative measures taken to avoid infection and bleeding

The preventative measures taken to avoid infection and bleeding as reported by subjects during open-ended interviews will be summarized.

Time frame: Up to 90 minutes

Number of caregiver reported preventative measures taken to avoid infection and bleeding

The preventative measures taken to avoid infection and bleeding as reported by caregivers during open-ended interviews will be summarized.

Time frame: Up to 90 minutes

Number of subject reported awareness on the risk of disease

Open-ended interviews will be conducted in adolescent and adult subjects to understand their awareness on the risk of disease (that is, risk of future complications and potential rapid decline).

Time frame: Up to 90 minutes

Number of caregiver reported awareness on the risk of disease

Open-ended interviews will be conducted in caregivers of WAS subjects to understand their awareness on the risk of disease (that is, risk of future complications and potential rapid decline).

Time frame: Up to 90 minutes

Number of treatment sequences received by subjects

Open-ended interviews will be conducted to understand the treatments received by subjects in terms of sequencing.

Time frame: Up to 90 minutes

Number of subject reported reasons for discontinuation or change in treatment option

Open-ended interviews will be conducted in adolescent and adult subjects to understand reasons for discontinuation or change in treatment option for WAS.

Time frame: Up to 90 minutes

Number of caregiver reported reasons for discontinuation or change in treatment option

Open-ended interviews will be conducted in caregivers of WAS subjects to understand reasons for discontinuation or change in treatment option for WAS.

Time frame: Up to 90 minutes

Analysis of tolerability of treatment by subjects

Open-ended interviews will be conducted in subjects and caregivers to understand the tolerability of WAS treatment by subjects.

Time frame: Up to 90 minutes

Number of subject reported treatment burden

Open-ended interviews will be conducted in adolescent and adult subjects to analyze treatment burden for subjects.

Time frame: Up to 90 minutes

Number of caregiver reported treatment burden

Open-ended interviews will be conducted in caregivers of WAS subjects to analyze treatment burden for caregivers.

Time frame: Up to 90 minutes

Number of subject reported perspectives on the risk associated with treatment

Open-ended interviews will be conducted in adolescent and adult subjects to understand their perspective on the risks associated with each treatment.

Time frame: Up to 90 minutes

Number of caregiver reported perspectives on the risk associated with treatment

Open-ended interviews will be conducted in caregivers of WAS subjects to understand their perspective on the risks associated with each treatment.

Time frame: Up to 90 minutes

Number of key concepts of interest

Open-ended interviews will be conducted to identify the important concepts of interest that may be used in future clinical trials.

Time frame: Up to 90 minutes

Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes